littermates (dark gray, n = 14). (e) Effects of the NMDA receptor antagonist MK-801 (MK, 0.03 mg per kg, intraperitoneal) on wild-type (black, n = 23; dark gray, n = 16) and Glu-CB 1 −/− littermates (KO; white, n = 9; light gray, n = 6). (f) Effects of the GABA A receptor antagonist picrotoxin (PTX, 0.3 mg per kg, intraperitoneal) on wild-type (black, n = 23; dark gray, n = 8) and GABA-CB 1 −/− littermates (KO; white, n = 22; light gray, n = 11). All data are expressed as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 as compared with wild-type littermate controls. ### P < 0.001. All experimental procedures were approved by the Committee on Animal Health and Care of INSERM and the French Ministry of Agriculture and Forestry (authorization number, 3306369). suggesting that feeding-activating internal states are necessary to cause these phenotypes. No alterations in fasting-induced food intake were found in Nex-cre and Dlx5/6-cre transgenic mice, the appropriate genetic controls of Glu-CB 1 −/− and GABA-CB 1 −/− mice, respectively 11,13,14 ( Supplementary Fig. 1 ). The food intake of Glu/GABA-CB 1 −/− double-mutant mice, in which CB 1 is deleted from both cortical glutamatergic and GABAergic neurons (Supplementary Figs. 2-5 ), did not differ from wild-type littermates (Fig. 1d) , indicating that the two genetic mutations compensate for each other in fasting-refeeding experiments. These results suggest that CB 1 -dependent control of glutamatergic or GABAergic transmission exerts opposite effects on stimulated food intake.
Anatomical analyses revealed that CB 1 mRNA was not expressed in the large majority of cortical glutamatergic neurons in Glu-CB 1 −/− mice 11 , in GABAergic neurons in GABA-CB 1 −/− mice 11 and in both neuronal populations in Glu/GABA-CB 1 −/− double mutants ( Supplementary  Figs. 2-6) . Notably, the lack of CB 1 mRNA expression resulted into an almost undetectable decrease in the levels of CB 1 protein in Glu-CB 1 −/− mice and in a strong reduction of CB 1 protein in GABA-CB 1 −/− mice ( Supplementary Fig. 7 ), confirming that the large majority of brain CB 1 receptors are expressed in GABAergic neurons 5 .
To exclude potential caveats associated with the use of genetic models, such as possible developmental alterations or undetected deletions of CB 1 receptors in additional brain areas or cell types 13, 14 , we carried out acute pharmacological studies in mutant mice and wild-type controls. Acute administration of an ineffective dose of the NMDA receptor antagonist MK-801 ( Supplementary Fig. 8 ) abolished the phenotype of Glu-CB 1 −/− mice (Fig. 1e) . Similarly, an ineffective dose of the GABA A receptor antagonist picrotoxin ( Supplementary Fig. 8 ) abolished the phenotype of GABA-CB 1 −/− mice (Fig. 1f) . These data suggest that the CB 1 -dependent acute inhibition of excitatory glutamatergic transmission contributes to fasting-induced hyperphagia, whereas inhibition of inhibitory GABAergic transmission mediates a hypophagic effect of endogenous CB 1 signaling.
The CB 1 agonist ∆ 9 -tetrahydrocannabinol (THC) exerted a biphasic effect on food intake in fasting-refeeding experiments (Supplementary Fig. 9) . Notably, the hyperphagic dose of THC (1 mg per kg of body weight) and the hypophagic one (2.5 mg per kg) did not alter locomotor activity during refeeding (Supplementary Fig. 9 ), indicating that altered locomotion was not involved in the effects of the drug. We then administered these doses of THC to CB 1 mutant mice and their wild-type littermates. Whatever the dose, THC was inactive in CB 1 −/− mice (Fig. 2a) . The hyperphagic dose of THC had no effect on Glu-CB 1 −/− mice, whereas the higher dose decreased food intake in these mutants (Fig. 2b) . Conversely, the lower dose of THC increased food intake in GABA-CB 1 −/− mice, whereas the higher dose did not induce hypophagia (Fig. 2c) . These results suggest that the orexigenic effect of a low dose of THC is mediated by CB 1 -dependent inhibition of glutamate release, whereas the hypophagic effect of the higher dose occurs via CB 1 -mediated inhibition of GABA release.
To further rule out possible confounding factors caused by the use of conditional mutant mice and to confirm the mechanism of the biphasic effects of THC, we carried out acute pharmacological studies in C57BL/6NCrl mice. The activation of CB 1 receptors by THC in either glutamatergic (low doses) or GABAergic neurons (high doses) should lead to a decreased release of the respective neurotransmitter, thereby reducing glutamatergic and GABAergic signaling, respectively 2, 3 (Supplementary Fig. 10 ). Theoretically, these effects could be compensated for by simultaneous treatment with allosteric enhancers of the respective receptors, which would strengthen the effects of the remaining synaptic neurotransmitters (Supplementary Fig. 10 ). An ineffective dose of the allosteric NMDA receptor enhancer d-cyclo-serine (Supplementary Fig. 11 ) fully reversed the hyperphagic effect of 1 mg per kg THC, but did not alter the hypophagic (Fig. 2d) . Conversely, an ineffective dose of the allosteric enhancer of the GABA A receptors diazepam (DZP; Supplementary Fig. 11 ) failed to change the hyperphagic effect of the low dose of THC, but fully reversed the hypophagic effect of 2.5 mg per kg THC (Fig. 2e) .
The ventral striatum controls food intake 6, 8 and contains substantial levels of CB 1 -positive axons 5 . These CB 1 -expressing fibers were still present in Glu-CB 1 −/− mice, but were absent in GABA-CB 1 −/− mice ( Supplementary Fig. 12 ). Bilateral injections ( Supplementary  Fig. 13 ) of the CB 1 antagonist AM251 (1 µg per site) into the ventral striatum of C57BL/6NCrl mice did not alter the hyperphagic effect of 1 mg per kg THC (Supplementary Fig. 13 ), but fully blocked the effect of the hypophagic dose of the drug (Fig. 2f) . Consistently, the local injection of an ineffective dose of DZP 8 also blocked the hypophagic effect of 2.5 mg per kg THC (Fig. 2f) . The latter effect was also blunted in CB 1 loxP/loxP; D1-cre mice (referred to as D1-CB 1 −/− mice) 12 ( Supplementary Fig. 14) , which lack CB 1 expression in a large fraction of striatal neurons 12 . Altogether, these data indicate that CB 1 -dependent inhibition of GABA release in the ventral striatum is necessary for the hypophagic effect of 2.5 mg per kg THC. Our findings reveal two unexpected opposing brain functions of CB 1 receptors in the regulation of stimulated food intake. First, the control of glutamatergic transmission by CB 1 receptors is responsible at least in part for the well-known orexigenic role of the ECS. Second, CB 1 receptors expressed on ventrostriatal GABAergic neurons mediate, by reducing local inhibitory transmission, a previously unknown inhibitory function of the ECS on stimulated food intake. Low or high amounts of (endo)cannabinoids might differentially affect these opposing CB 1 -dependent effects. The overall orexigenic role of the ECS on stimulated ingestive behavior seems to be the end product of finely regulated opposite functions. It is presently unknown how endogenous and/or exogenous CB 1 agonists could select the neuronal type in which they exert these opposing effects. The pharmacology of CB 1 receptors might vary according to the neuronal populations in which they are expressed. For example, possible cell type-specific heterodimerizations and/or conformational states of CB 1 receptors 15 might determine different cannabinoid-mediated intracellular responses. In conclusion, our findings reveal a bimodal mode of action of the ECS and exogenous cannabinoids in the control of stimulated food intake and underscore the importance of the ECS-mediated finetuned control of neuronal excitation and inhibition for the regulation of behavior in mammals.
Note: Supplementary information is available on the Nature Neuroscience website.
